Table 1.

Efficacy of BCR-ABL tyrosine kinase inhibitors by disease stage

PhaseCHRMCyRCCyRMMRMedian OS (mo)OS at 12 monthsRef.
Blast crisis
 ImatinibI11%5%0%7
 ImatinibI/II23%3%8%6.522%8
 ImatinibII15%16%7%6.932%9
 DasatinibaII27%36%26%11.850%10
 NilotinibaI6%18%6%11
Accelerated-phase relapse
 ImatinibII53%24%17%NR74%12
 DasatinibaII39%33%24%NR74%b13
Previously treated chronic phase
 ImatinibI77%31%13%14
 ImatinibIII82%55%39.6%cNR>97%15, 16
 DasatinibaII91%59%49%NR>96%17
Newly diagnosed chronic phase
 ImatinibIII95%85%73.8%cNR>97%15, 16
 ImatinibIII66%d28%dNR99%18
 ImatinibIII65%d22%dNR19
 DasatinibIII77%d46%dNR97%18
 NilotinibIII79%d44%d19

Abbreviations: CCyR, complete cytogenetic response; CHR, complete hematologic response; MCyR, major cytogenetic response; MMR, major molecular response; OS, overall survival; NR, not reached; —, not reported.

  • aImatinib-resistant or intolerant.

  • bProgression-free survival at 12 months.

  • cBest observed response.

  • dResponse at 12 months.